生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK4139 生物科技

已收盘 06-22 16:00:00 EDT

1,164.02

+35.23

+3.12%

最高1,167.17	最低1,135.15	成交量37.85亿
今开1,135.17	昨收1,128.80	日振幅2.84%
总市值0.00	流通市值0.00	总股本0.00
成交额286.52亿	换手率--	流通股本0.00
市净率6.881147	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"生物科技","latestPrice":1164.0245,"timestamp":1782158399999,"preClose":1128.7953,"halted":0,"volume":3784650153,"delay":0,"changeRate":0.03121,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":35.229248,"latestTime":"06-22 16:00:00 EDT","open":1135.1748,"high":1167.1666,"low":1135.1539,"amount":28652183304.407185,"amplitude":0.02836,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1782172800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.881147,"peRate":-153.406997,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK4139/tweets","defaultTab":"tweets","newsList":[{"id":"1141922913","title":"Arrowhead Pharmaceuticals获欧盟批准Redemplo® (Plozasiran)用于降低家族性乳糜微粒血症综合征成人患者甘油三酯","url":"https://stock-news.laohu8.com/highlight/detail?id=1141922913","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141922913?lang=zh_cn&edition=full","pubTime":"2026-06-23 00:34","pubTimestamp":1782146067,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals宣布，其药物Redemplo® (Plozasiran)已获得欧盟委员会授予的上市许可，用于降低患有家族性乳糜微粒血症综合征（FCS）的成人患者的甘油三酯水平。FCS是一种罕见且严重的遗传性疾病，其特征是血液中甘油三酯水平极度升高，可导致危及生命的胰腺炎。该授权标志着Arrowhead Pharmaceuticals在罕见病治疗领域取得的重要进展，为欧洲的FCS患者提供了一种新的治疗选择。公司表示，将致力于尽快将这一创新疗法带给有需要的患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ARWR","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645076352","title":"DNA比对成功！确认是义乌这一家！","url":"https://stock-news.laohu8.com/highlight/detail?id=2645076352","media":"爱义乌","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645076352?lang=zh_cn&edition=full","pubTime":"2026-06-22 22:00","pubTimestamp":1782136800,"startTime":"0","endTime":"0","summary":"近日稠江街道西王界村夏关兴、柯玲香家迎来大喜事老两口采血入库等待5年终于找到了失散50年的女儿朱雪峰当天上午10点，江滨公园青年吧前，50岁的朱雪峰与82岁的母亲柯玲香见面后，双方紧紧相拥，泪水打湿了彼此的肩头。幸运的是，几十年来，夏关兴、柯玲香夫妇也始终没有放弃找寻失散的女儿。2021年，得知DNA采血比对能够助力寻亲后，二人马上提交血样完成数据库登记。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-06-22/doc-inieiatn2393812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4121","BK4109","BK4139","DNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104351212","title":"Canaccord Genuity下调Apogee Therapeutics评级至持有，目标价上调至135.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1104351212","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104351212?lang=zh_cn&edition=full","pubTime":"2026-06-22 21:21","pubTimestamp":1782134474,"startTime":"0","endTime":"0","summary":"投资机构Canaccord Genuity调整了对生物技术公司Apogee Therapeutics (APGE)的股票评级。该机构将评级从“买入”下调至“持有”，但同时将其目标股价从130美元上调至135.11美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APGE","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176285178","title":"创新医疗技术控股公司获FDA新许可扩大Adapt试验，并快速推进Olastrocel治疗慢性下背痛的三期规划","url":"https://stock-news.laohu8.com/highlight/detail?id=1176285178","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176285178?lang=zh_cn&edition=full","pubTime":"2026-06-22 21:15","pubTimestamp":1782134122,"startTime":"0","endTime":"0","summary":"创新医疗技术控股公司在获得美国食品药品监督管理局的新许可后，已着手扩大其Adapt临床试验的范围。与此同时，公司正迅速推进其核心候选产品Olastrocel用于治疗慢性下背痛的第三期临床试验规划。此次监管进展为Adapt试验的扩展扫清了障碍，标志着公司在该治疗领域的研究迈出了关键一步。Olastrocel作为一种针对慢性疼痛的细胞疗法，其后续开发进程也因此获得显著加速。公司管理层表示，快速向三期试验迈进是基于此前获得的积极数据与FDA的持续反馈。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146349619","title":"艾伯维CEO称Apogee收购是“绝佳契合”，符合构建产品管线及为2030年代以后增添新增长动力的战略","url":"https://stock-news.laohu8.com/highlight/detail?id=1146349619","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146349619?lang=zh_cn&edition=full","pubTime":"2026-06-22 21:07","pubTimestamp":1782133664,"startTime":"0","endTime":"0","summary":"艾伯维首席执行官表示，对Apogee的收购交易与公司战略“绝佳契合”。该战略旨在构建强大的产品管线，并为2030年代及更远的未来增添新的增长驱动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B42XCP33.USD","BK4533","LU1037948897.HKD","IE00B3PB1722.GBP","IE00BN8TJ469.HKD","BK4534","SG9999015986.USD","LU0738911758.USD","LU0868494708.USD","IE0002270589.USD","LU1934455863.HKD","LU2087621335.USD","LU0545039389.USD","LU0170899867.USD","LU0057025933.USD","BK4588","LU1839511570.USD","IE00BJJMRZ35.SGD","LU2357627491.SGD","IE000SO60NU8.SGD","LU0158827948.USD","LU0256863902.USD","IE00B2B36J28.USD","LU0965509010.AUD","LU0965509101.SGD","LU0114720955.EUR","LU0511384066.AUD","LU0868494617.USD","LU0234572021.USD","LU0203345920.USD","LU1670627923.USD","LU2112291526.USD","LU0289961442.SGD","LU2237443549.SGD","LU1989771016.USD","LU2023251221.USD","LU0661504455.SGD","IE0000B7K699.USD","LU1074936037.SGD","LU0708994859.HKD","LU0912757837.SGD","LU2237443382.USD","LU0795875086.SGD","LU0689626769.HKD","LU0456855351.SGD","LU0553294199.USD","LU1989772923.USD","LU0211327993.USD","LU1983299246.USD","LU0310800379.SGD","LU0949170772.SGD","LU0256863811.USD","LU0320765646.SGD","BK4559","LU0795875169.SGD","LU0128525929.USD","LU1037948541.HKD","LU0289739699.SGD","LU2347655156.SGD","IE000MB6IJN5.SGD","LU0198837287.USD","LU2133065610.SGD","LU0965509283.SGD","LU1093756325.SGD","LU1551013342.USD","IE00BSNM7G36.USD","LU0029864427.USD","LU2237443978.SGD","LU1934455194.USD","LU0820561818.USD","LU0965508806.USD","LU2237443622.USD","LU2089984988.USD","LU0943347566.SGD","BK4139","LU1585245621.USD","LU1267930573.SGD","LU2089284900.SGD","LU1989772840.SGD","LU1023059063.AUD","LU0122379950.USD","LU0820561909.HKD","SG9999015978.USD","LU1670628061.USD","LU2129689431.USD","BK4550","SG9999001440.SGD","LU0211328371.USD","IE00BLSP4239.USD","BK4581","LU1732799900.SGD","IE00BBT3K403.USD","LU0859254822.USD","IE0002141913.USD","IE00BLSP4452.SGD","LU0861579265.USD","LU0124676726.USD","LU0098860793.USD","LU0823416689.USD","IE00B19Z3B42.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","SG9999003800.SGD","IE00B4R5TH58.HKD","BK4566","LU1732800096.USD","IE00BDGV0183.EUR","LU1003077747.HKD","LU0069063385.USD","LU1718418525.SGD","LU1551013425.SGD","LU2129689514.USD","IE000BZT7R73.USD","LU0234570918.USD","LU2129689605.HKD","IE00BVYPNV92.GBP","LU2089283258.USD","SG9999011175.SGD","LU1057294990.SGD","LU0472753341.HKD","IE00B19Z3581.USD","LU0432979614.USD","LU0882574055.USD","LU2237443895.HKD","IE000F7OJYX1.SGD","LU0985320562.USD","IE0009355771.USD","LU0689472784.USD","LU1061106388.HKD","LU1244550221.USD","LU0310799852.SGD","IE00BVYPNW00.USD","LU1430594728.SGD","LU1093756168.USD","LU0942090050.USD","LU1934455277.USD","LU0203347892.USD","LU0289739343.SGD","LU1496350502.SGD","BK4585","LU1244550494.USD","LU0058720904.USD","LU1267930490.SGD","LU2237443465.HKD","LU2468319806.SGD","LU1496350171.SGD","IE0004445239.USD","LU1162221912.USD","IE000WAW04H5.SGD","IE00BGHQF631.EUR","SG9999015945.SGD","LU1244550577.SGD","SG9999015952.SGD","LU1291159041.SGD","LU1929549753.HKD","LU0417517546.SGD","ABBV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175661512","title":"Capstone Holding Corp 获1.15亿美元循环信贷额度展期至2026年底，夹层融资延至2028年","url":"https://stock-news.laohu8.com/highlight/detail?id=1175661512","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175661512?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:32","pubTimestamp":1782131537,"startTime":"0","endTime":"0","summary":"Capstone Holding Corp 宣布，其价值1.15亿美元的循环信贷额度已成功展期，新的到期日定为2026年12月31日。与此同时，公司旗下的夹层融资安排也获得了延长，有效期将延续至2028年9月30日。这一系列融资条款的调整，为公司的中期运营与战略发展提供了更为充裕的资金灵活性和稳定性。信贷额度的展期有助于企业优化债务结构，而夹层融资期限的延长则可能支持其长期资本项目或增长计划，进一步巩固了公司的财务基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPS","BK4104","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151073597","title":"格陵兰矿业与Nordisk Fundering签署钻探合同 扩大2026年格陵兰Skaergaard金刚石钻探计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1151073597","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151073597?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:32","pubTimestamp":1782131529,"startTime":"0","endTime":"0","summary":"格陵兰矿业公司已与Nordisk Fundering签订了一份钻探合同，旨在扩大其于2026年在格陵兰Skaergaard项目进行的金刚石钻探计划。这一合作标志着该公司对其在格陵兰的矿产勘探活动进行了重要扩展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRML","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645222700","title":"再生元制药(REGN)重症肌无力创新药获美欧监管受理  有望成全球首款治疗该症的siRNA药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2645222700","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645222700?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:32","pubTimestamp":1782131526,"startTime":"0","endTime":"0","summary":"该药用于治疗抗乙酰胆腺受体抗体阳性的成人全身型重症肌无力患者。作为一款针对补体系统C5靶点的小干扰RNA疗法，Cemdisiran若能获批，有望成为全球首款用于治疗gMG的siRNA药物。目前，Cemdisiran仍处于临床研究阶段，其安全性和疗效尚未获得任何国家监管机构的最终批准。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/OTA0YzE0M2JmNDRmODg4Nzg5OWVhODM3NzhmNzU4MTEwODUxNDg2MTkzOA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/OTA0YzE0M2JmNDRmODg4Nzg5OWVhODM3NzhmNzU4MTEwODUxNDg2MTkzOA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301751","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU2468319806.SGD","LU0882574055.USD","LU2106854487.HKD","LU2089984988.USD","LU2362541513.USD","06978","BK1574","LU1917777945.USD","BK4139","LU0109394709.USD","BK1191","LU0114720955.EUR","LU2362540622.SGD","BK4588","BK1161","01477","LU0289739699.SGD","LU0320765992.SGD","LU0889565916.HKD","LU2023250504.SGD","LU2237438978.USD","LU0053666078.USD","LU0823434740.USD","REGN","159992","LU1974910355.USD","LU0823434583.USD","LU2362541273.HKD","LU0823416689.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176989506","title":"bioAffinity Technologies公布积极临床前结果：专有基因沉默技术选择性杀伤鳞状皮肤癌细胞，不损伤健康细胞","url":"https://stock-news.laohu8.com/highlight/detail?id=1176989506","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176989506?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:06","pubTimestamp":1782129966,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies公司报告了积极的临床前研究结果，其专有的基因沉默技术展现出了对鳞状皮肤癌细胞的细胞毒性，同时不会对健康细胞造成伤害。这项技术显示出高度的选择性，为针对此类癌症的精准疗法开发提供了新的可能性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAFW","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144802167","title":"Taysha Gene Therapies：12个月时，100%的Reveal Part a患者获得或重获发育里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1144802167","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144802167?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:05","pubTimestamp":1782129939,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies公司宣布，其Reveal Part a研究中的所有患者，在12个月时均获得或重获了关键的发育里程碑。这一数据展现了该公司基因疗法在临床开发中的积极进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645408024","title":"再鼎医药(09688)授出受限制股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2645408024","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645408024?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:05","pubTimestamp":1782129907,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，公司于2026年6月17日(美国东部时间)根据2024年股权激励计划获授人授出部分受限制股份。所授出受限制股份数目(以美国存托股份计)：178,968。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09688","LU2488822045.USD","BK1574","BK4588","BK4548","BK1161","ZLAB","BK4531","BK4139","BK4526","BK4585","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166319039","title":"伊克力西斯公布Zanzalintinib联合免疫检查点抑制剂治疗转移性结直肠癌的III期Stellar-303试验最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1166319039","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166319039?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:02","pubTimestamp":1782129739,"startTime":"0","endTime":"0","summary":"伊克力西斯公司近日公布了其III期Stellar-303临床试验的最新情况。该试验旨在评估Zanzalintinib与一种免疫检查点抑制剂联合疗法，在治疗转移性结直肠癌患者中的疗效与安全性。这一更新为关注该药物研发进程的投资者与医学界提供了重要信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EXEL","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199614831","title":"知临集团宣布Diamir Biosciences与Alzlabs Precision Diagnostics就阿尔茨海默病生物标志物达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1199614831","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199614831?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:01","pubTimestamp":1782129686,"startTime":"0","endTime":"0","summary":"知临集团宣布，旗下公司Diamir Biosciences与Alzlabs Precision Diagnostics已达成一项合作，旨在共同开发用于阿尔茨海默病的生物标志物。此项合作将结合双方在诊断技术及生物标志物发现领域的专长，以推进针对该神经退行性疾病的精准检测方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131729514","title":"Kyverna Therapeutics任命Ritesh Srivastava为首席法律与合规官，强化领导团队以支持商业化阶段转型","url":"https://stock-news.laohu8.com/highlight/detail?id=1131729514","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131729514?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:01","pubTimestamp":1782129684,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics已正式任命Ritesh Srivastava担任公司首席法律与合规官。这一关键人事任命旨在显著增强公司的领导层实力，为其向商业化阶段的战略转型提供坚实支撑。Srivastava先生将负责领导公司的整体法律事务、合规体系构建以及企业治理工作，其丰富的专业经验预计将为Kyverna Therapeutics下一阶段的发展带来重要助力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130410441","title":"Prime Medicine 旗下 PM359 获美 FDA 再生医学先进疗法认定，用于治疗慢性肉芽肿病","url":"https://stock-news.laohu8.com/highlight/detail?id=1130410441","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130410441?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:01","pubTimestamp":1782129682,"startTime":"0","endTime":"0","summary":"Prime Medicine 公司宣布，其用于治疗慢性肉芽肿病的在研疗法 PM359 已获得美国食品药品监督管理局授予的再生医学先进疗法认定。这一认定旨在加速针对严重疾病且初步临床证据显示有潜力满足未竟医疗需求的再生医学疗法的开发与审评。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180909008","title":"Taysha基因疗法公司宣布Reveal关键试验完成给药，并公布评估TSHA-102治疗Rett综合征的Reveal 1/2期试验A部分的长期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1180909008","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180909008?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:01","pubTimestamp":1782129682,"startTime":"0","endTime":"0","summary":"Taysha基因疗法公司宣布，其评估TSHA-102治疗Rett综合征的Reveal关键临床试验已完成患者给药。同时，该公司还公布了来自Reveal 1/2期试验A部分的更长期临床数据。\n该消息标志着Taysha在推进其基因疗法候选药物TSHA-102方面取得了重要进展。关键试验的完成是药物开发过程中的一个关键节点，为后续的数据分析和潜在的监管提交奠定了基础。\n此外，从早期试验阶段获得的更长期数据，有望为TSHA-102的安全性和有效性提供更深入的见解，这对于评估该疗法的持久潜力至关重要。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179995011","title":"Regenxbio Inc预计7月召开A类会议 并计划会后于2026年第三季度迅速重新提交BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=1179995011","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179995011?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:40","pubTimestamp":1782128441,"startTime":"0","endTime":"0","summary":"Regenxbio Inc 近日表示，公司预计将在今年7月与美国食品药品监督管理局（FDA）举行一次A类会议。此次会议旨在就相关生物制品许可申请（BLA）进行关键讨论。\n在会议结束后，公司计划迅速行动，于2026年第三季度内重新提交该BLA申请。这一时间表凸显了公司推进其研发管线的决心与效率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","RGNX","BK4139","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154362997","title":"Regenxbio：与FDA就Naxsunli潜在加速批准所需后续步骤达成一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1154362997","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154362997?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:40","pubTimestamp":1782128436,"startTime":"0","endTime":"0","summary":"Regenxbio公司表示，已与美国食品药品监督管理局（FDA）就基因疗法Naxsunli获得潜在加速批准所需的后续步骤达成共识。公司发言人指出，双方已明确后续行动方向，为推进该疗法的审评进程奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","BK4563","RGNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190851505","title":"Nuvectis Pharma与海思科达成协议：后者将获高达4000万美元首付款及近期款项，并有资格获取总额达14.21亿美元的里程碑付款与分级特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1190851505","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190851505?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:35","pubTimestamp":1782128156,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma, Inc.与海思科医药集团股份有限公司（Haisco Pharmaceutical Group Co.,Ltd.）已达成一项重要合作协议。根据协议条款，海思科将获得总额高达4000万美元的首付款及近期阶段性款项。此外，海思科还有资格在未来基于特定研发、注册及商业化里程碑的实现，获取累计最高达14.21亿美元的额外付款。该协议同时包含分级特许权使用费安排，进一步提升了海思科在合作项目成功商业化后的潜在收益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT","BK0033","002653","BK0239","BK0028","BK0188","BK4139","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130696460","title":"Nuvectis Pharma 协议附带融资条件，要求公司确保资本充足","url":"https://stock-news.laohu8.com/highlight/detail?id=1130696460","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130696460?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:35","pubTimestamp":1782128140,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma, Inc. 达成的一项协议附带了融资前提条件，该条件要求公司必须确保拥有充足的资本来完成相关安排。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"name":"生物科技","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK4139,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}